Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FoxHollow Stock Up 25% In Q3 On SilverHawk Profitability, Merck Deal

This article was originally published in The Gray Sheet

Executive Summary

FoxHollow's stock advanced 25.1% in the third quarter as investors took notice of the firm's first profitable quarter, increased adoption of the company's SilverHawk peripheral vessel plaque excision system and an expanded research agreement with Merck

You may also be interested in...

Device Newcomer And Pharma Giant Expand Partnership

Merck is buying an 11% stake in device maker FoxHollow, expanding a previous agreement to use plaque isolated from patients' arteries for pharmaceutical research

FoxHollow Finds Rinspiration For Cardiac Market Entry Via Kerberos Purchase

FoxHollow's acquisition of the Rinspiration thrombectomy device through its $32 mil. purchase of Kerberos Proximal Solutions provides the firm with immediate access to the coronary market

Candela Looks To Multi-Use Laser Platform To Help Sustain Growth

Medical and aesthetic laser manufacturer Candela plans to launch a "multi-configuration, multi-application" system early next year to help the firm sustain sales growth at or above the 15%-18% range, according to the company

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts